Skip to content

Antibacterial effects of chlorhexidine , persica and saline mouthwashes

Comparison of the immediate Antibacterial Effects of persica , Chlorhexidine and normal saline Mouthwash in ICU patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT138903254190N1
Enrollment
60
Registered
2010-12-29
Start date
2010-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: ventilator associated pneumonia. Condition 2: ventilator associated pneumonia. Pneumonia due to Streptococcus pneumoniae Pneumonia due to staphylococcus

Interventions

Intervention 1: In first group, will used chlorhexidine gluconate 0.2% mouthwash, manufactured by pharmaceutical company of drug city (Tehran – Iran).all surfaces of mouth, gingiva, tongue, throat and
In first group, will used chlorhexidine gluconate 0.2% mouthwash, manufactured by pharmaceutical company of drug city (Tehran – Iran).all surfaces of mouth, gingiva, tongue, throat and teeth will be s
In second group, will used persica 10% mouthwash, manufactured by pharmaceutical company of pursina. all surfaces of mouth, gingiva, tongue, throat and teeth will be swapped carefully by 10 cc of mout
In third group, will used normal salin mouthwash. all surfaces of mouth, gingiva, tongue, throat and teeth will be swapped carefully by 10 cc of mouthwashes (normal salin) for 6 minutes. Immediately b

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 15-65 years, Third and fourth day of admission in ICU, Intubation and mechanical ventilation for 3 to 4 days, having NG tube for 3 to 4 Exclusion Criteria: Re-intubation, History of antibiotic therapy before admission, Oral anticoagulation therapy,Respiratory and systemic infection, Autoimmune diseases and malignancies, History of allergy to mouthwash, asthma, allergic rhinitis and dermatitis, History of radiation therapy and immunosuppressive therapy including corticosteroid, Use of any kind of antimicrobial mouthwash within 2 months before admission, Diseases of oral mucosa and severe periodontitis, History of splenectomy and Tonsillectomy , Negative cultures of S.aureus and pneumoccocus before use of mouthwash, Occurrence of any reaction to Mouthwashes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Number of colony of S.aureus and pneumoccocus. Timepoint: Immediately before and after using mouthwashes. Method of measurement: CFU(Colony-forming unit).

Secondary

MeasureTime frame
Any reaction to Mouthwashes. Timepoint: after using of mouthwashes. Method of measurement: inspection.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Darvishi Khezri

Mazandaran University Of Medical Sciences

H.darvishi@mazums.ac.ir ; Hadidarvishi87@yahoo.com+98 15132612458

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026